Incyte Corporation

Incyte Holdings Corporation

Vaqar Sharief

Zhongjiang Jia

Yongchun Pan

Jiacheng Zhou

Ganfeng Cao

Michael Xia

Lei Qiao

Qiyan Lin

Chongsheng Eric Shi

Qun Li

Changsheng Zheng

Pingli Liu

David J Meloni

William Frietze

Lingkai Weng

Tai-Yuen Yue

Wayne Han

Jianji Wang

The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.

Salts of a Pim kinase inhibitor

The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3Kδ), as well as a salt form and intermediates related thereto.

Salts and processes of preparing a PI3K inhibitor

The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.

Salts of an LSD1 inhibitor

Salts of a pim kinase inhibitor

Growing community of inventors

Newark, DE, United States of America

Vaqar Sharief